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Abstract
Foot-and-mouth disease virus (FMDV) isolate C1-Barcelona (or C-S30) includes four replacements within its immunodominant
site (GH loop, residues 136–150 of capsid protein VP1, YTTSTRGDLAHVTAT), relative to reference strain C-S8c1 (YTASAR-
GDLAHLTTT). Although one of the mutations in C-S30 (147LeuVal) is known to be detrimental for antibody recognition,
reactivity of this isolate with the neutralizing monoclonal antibody (mAb) 4C4, raised against FMDV C1-Brescia (GH loop:
YTASTRGDLAHLTAT), was indistinguishable from those of strains C-S8c1 or C1-Brescia. A structural interpretation for these
somewhat striking findings is available, based on the observation that 15-residue peptides reproducing the C-S30 and C-S8c1 GH
loops adopt very similar, quasi-circular, conformations in crystal complexes with 4C4. Nevertheless, surface plasmon resonance
(SPR) kinetic analyses of the interactions between these peptides and three anti-GH loop mAbs have now revealed that the linear
C-S30 peptides were less antigenic in solution than their C-S8c1 and C1-Brescia counterparts. We have, therefore, tried to
modulate peptide antigenicity in solution by cyclization. Functional SPR and structural two dimensional proton nuclear magnetic
resonance (2D-1H NMR) studies of both linear and cyclic peptide antigens are discussed here. Conformation seems to have an
important role in peptide antigenicity, even when continuous (i.e. linear) antigenic sites are involved. © 2001 Elsevier Science Ltd.
All rights reserved.
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1. Introduction
Foot-and-mouth disease virus (FMDV), an aph-
thovirus from the Picornairidae family, causes the
economically most important disease of farm animals
[1] and is characterized by an extremely high antigenic
and genetic variability that gives rise to seven serotypes
and over 65 subtypes. In serotype C, neutralizing anti-
Abbreiations: 2D-1H NMR, two-dimensional proton nuclear magnetic resonance; AA, amino acid residue; AAA, amino acid analysis; Ahx,
6-aminohexanoic acid; AM, 2-[4-aminomethyl-(2,4-dimethoxyphenyl)]phenoxyacetic acid (linker); CA, analyte concentration; H, conforma-
tional chemical shift for proton ; DIEA, diisopropylethylamine; DMF, N,N -dimethylformamide; EDC, N-ethyl-N -dimethylaminopropylcar-
bodiimide; EID, enzyme immunodot; EITB, enzyme immuno-electrotransfer blot; ESIMS, electrospray ionization mass spectrometry; Et3Si,
triethylsilane; Fab, fragment antigen binding; FMDV, foot-and-mouth disease virus; Fmoc, 9-fluorenylmethoxycarbonyl; HPLC, high perfor-
mance liquid chromatography; IC50, 50% inhibition concentration; ka, association rate constant (M
−1s−1); KA, association thermodynamic
constant (M−1); kd, dissociation rate constant (s
−1); KD, dissociation thermodynamic constant (M); KLH, keyhole limpet hemocyanin; Ki,
solution affinity constant (M−1); mAb, monoclonal antibody; MALDI-TOF MS, matrix-assisted laser desorption — time-of-flight mass
spectrometry; MBHA, p-methylbenzhydrylamine resin; MeCN, acetonitrile; NHS, N-hydroxysuccinimide; NMM, N-methylmorpholine; NOE,
nuclear Overhauser effect; PBS, phosphate buffer saline; Req, equilibrium response; RI, bulk refractive index; Rimmob, immobilization response;
Rmax, maximum response (RU); RPLC, reverse phase liquid chromatography; RU, resonance units; SPPS, solid phase peptide synthesis; SPR,
surface plasmon resonance; tBu, tert-butyl; TBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; TFA, trifluoroacetic
acid; TFE, 2,2,2-trifluoroethanol.
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Table 1
Synthetic peptide mimics of the GH loops from serotype C FMD viruses
CommentsPeptide Sequence
A15S8c1 GH loop of FMDV C-S8C1YTASARGDLAHLTTT
A15Brescia GH loop of FMDV C1-Brescia––––T––––––––A–
GH loop of FMDV C-S30––T–T––––––V–A–A15S30
GH loop of FMDV C-S30 (cyclic)cyc16S30a,b (C––T–T––––––V–AXC)
a X stands for a 6-aminohexanoic acid residue.
b Parenthesis stand for an intra-molecular Cys–Cys bond (cyclic peptide).
bodies recognize FMDV GH loop (residues 136–150 of
capsid protein VP1 [2]), which includes several overlap-
ping linear epitopes [3] and is also termed antigenic site
A. Site A includes highly conserved residues, such as an
Arg-Gly-Asp (RGD) motif, and two leucines (144Leu,
147Leu), which are deeply involved in cell and antibody
recognition events [4]. This immunodominant region
can be faithfully reproduced by synthetic linear pep-
tides with the sequences found in the different virus
isolates [5–7]. Thus, the GH loop of FMDV C1-Santa
Pau Sp/70 (C-S8c1) is reproduced by peptide A15S8c1
(YTASARGDLAHLTTT, Table 1). The interactions of
this peptide with neutralizing monoclonal antibodies
(mAb), such as SD6 (raised against C-S8c1), 4C4 or
3E5 (both raised against C1-Brescia), have been fully
characterized by means of enzyme-linked immunosor-
bent assays (ELISA), surface plasmon resonance (SPR)
biosensor analysis and X-ray crystallographic studies
[8–11]. This peptide displayed high reactivity with both
mAbs and acquired a quasi-circular conformation when
in crystal complexes with both fragment antigen bind-
ing (Fab) fragments of SD6 and 4C4.
Recent crystallographic studies showed that another
peptide representing the GH loop of the variant isolate
C-S30 (peptide A15S30, YTTSTRGDLAHVTAT) also
adopts this quasi-circular conformation in the crystal
complex with Fab 4C4 [12]. Earlier immuno-enzymatic
studies had also shown that keyhole limpet hemocyanin
(KLH) conjugates of 21-mer peptides reproducing the
GH loops of C-S30, C-S8c1 and C1-Brescia strains [13]
were all recognized by mAb 4C4 to a similar extent.
Relative to strain C-S8c1, FMDV C-S30 includes four
mutations within the GH loop, two of them also
present in FMDV C1-Brescia (140AlaThr, 149Thr
Ala). The fact that one of these mutations, 147Leu
Val, is known to be detrimental for antibody and cell
recognition, makes the C-S30 peptides interesting
targets in the study of antigen–antibody recognition
mechanisms.
In this work, we have functionally characterized the
antibody recognition patterns of FMDV strain C-S30
by SPR analysis of representative synthetic peptides.
While SPR binding data on peptide A15S30 (YTTSTR-
GDLAHVTAT) and mAb SD6 were totally self-consis-
tent, its reactivity towards 4C4 was surprisingly lower
than those of peptides A15S8c1 (YTASARGD-
LAHLTTT) or A15Brescia (YTASTRGDLAHLTAT).
In view of these unexpected results, we studied the
A15S30 — mAb interaction in solution by means of a
solution affinity SPR experiment. Finally, as done ear-
lier for a C-S8c1-derived peptide [14], we have intro-
duced conformational restrictions in the C-S30 loop, by
means of an intramolecular disulfide bridge. The result-
ing cyclic peptide reproduces to a good extent the SPR
binding behavior expected from earlier data, and its
structural analysis by 2D-1H NMR is consistent with
the adoption of a native-like conformation.
2. Materials and methods
2.1. Peptides
Linear peptides A15S8c1, A15Brescia, A15S30 and
the dithiol precursor of cyc16S30 (Table 1) were
synthesized by SPPS as C-terminal carboxamides on
an AM-MBHA resin (0.51 mmol g−1) using 9-
fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) chem-
istry [15,16]. The synthesis scale was 0.1 mmol and
couplings were done with 4, 4 and 8 equivalents of
Fmoc-amino acid residue (AA)-OH, 2-(1H-benzotria-
zole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(TBTU) and diisopropylethylamine (DIEA), respec-
tively. A 20% piperidine solution in N,N -dimethylfor-
mamide (DMF) was used for the Fmoc deprotection
steps. Peptides were fully deprotected and cleaved from
the resin with trifluoroacetic acid/triethylsilane/H2O
(TFA/Et3Si/H2O) (95:2.5:2.5 v/v) for 2 h. The peptides
were isolated from the cleavage solution by precipita-
tion with cold tBu methyl ether, solubilized in diluted
HOAc, lyophilized and purified by reverse phase liquid
chromatography (RPLC) using a linear 525% gradi-
ent of acetonitrile (MeCN) into 0.05% TFA in water.
Purified products were satisfactorily characterized by
amino acid analysis (AAA), high performance liquid
chromatography (HPLC) and electrospray ionization
mass spectrometry (ESIMS). Cyclization of cyc16S30
was done by air oxidation of the free thiol groups at 50
M peptide in 100 mM NH4HCO3, pH 8. The reaction
was stopped by addition of glacial acetic acid after 2 h.
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After several lyophilization steps the cyclic disulfide
peptide was isolated and characterized as above.
Stock solutions (ca. 2.5 mM) of the above peptides in
0.1 M acetic acid were prepared and quantitated by
AAA. For SPR analysis, 1000-fold and subsequent
serial dilutions in HBS of the stock solutions were used.
2.2. Monoclonals and Fab fragments
Monoclonals SD6 and 4C4 and their Fab fragments
were a gift from Drs Wendy Ochoa and Nuria Verda-
guer, IBMC/CSIC, Barcelona, Spain. Stock solutions in
phosphate buffer saline (PBS) with 0.02% sodium azide,
pH 7.3 were quantitated by the Pierce BCA assay
(Pierce & Co.). Solutions for mAb immobilization (in
10 mM acetate buffer, pH 5.0) had a 5 g ml−1 final
concentration.
Monoclonal 3E5 was purified from ascitic fluid
(kindly supplied by Dr Emiliana Brocchi, IZSLE,
Brescia, Italy) using a HiTrap Protein A affinity
column (Pharmacia Biotech) and quantitated spec-
trophotometrically [1 OD280=0.75 mg ml−1]. The
mAb was concentrated by precipitation in 45%
(NH4)2SO4, resuspension and dialysis in PBS to give 3
mg mAb in 2 ml PBS. To obtain the Fab fragment, this
solution was incubated at 37°C for 5 h with 30 g of
papain (Sigma), 24 l of 100 mM EDTA and 126 l of
100 mM cysteine in a total volume of 3 ml PBS.
Digestion was quenched with iodoacetamide (180 l)
and proteins were precipitated by 85% (NH4)2SO4 and
centrifugation at 10000 rpm for 20 min; the pellet was
re-suspended in the minimum volume of 1:1 PBS:buffer
A and dialyzed overnight against buffer A (112.4 g l−1
glycine, 175.4 g l−1 NaCl, pH 8.9). The protein solu-
tion was passed through the HiTrap Protein A column;
the eluate was concentrated on Centriprep-3 (Amicon)
and recromatographed on Sephadex G-100 (PBS); Fab-
containing fractions were pooled, concentrated and
quantitated by optical density at 280 nm.
2.3. Surface plasmon resonance analysis
2.3.1. Direct single-step kinetic analysis on mAb
surfaces
BIAcore 1000 instrument, CM5sensor chips, HBS
buffer (10 mM Hepes with 0.15 M NaCl, 3.4 mM
EDTA and 0.005% surfactant P20 at pH 7.4), amine
coupling kit (NHS, N-hydroxysuccinimide; EDC, N-
ethyl-N -dimethylaminopropylcarbodiimide) and
ethanolamine were all from Biosensor AB. Immobiliza-
tion of mAbs was performed according to the manufac-
turer’s instructions, a 5 l min−1 HBS continuous flow
was maintained and the carboxymethyl surface was
activated by a 7-min injection of a solution containing
0.2 M EDC and 0.05 M NHS; biospecific surfaces were
obtained by injecting 35 l of the mAb solutions;
unreacted activated groups were blocked by a 6-min
injection of ethanolamine and remaining non-covalently
bound molecules were washed off with a 3-min pulse of
100 mM HCl for SD6 or 10 mM NaOH for 4C4 and
3E5 surfaces. Final surface densities were typically
around 1500 resonance units (RU).
All kinetic SPR analyses were run at a 60 l min−1
HBS flow and each peptide was injected at six different
concentrations, ranging from ca. 80–2500 nM for SD6,
ca. 40–1250 nM for 4C4 and ca. 20–625 nM for 3E5
surfaces. Sensorgrams were generated by injections of
peptide solutions with 90 s association steps followed
by 240 s dissociation in running buffer (kinjection
mode). A 90 s pulse of 100 mM HCl or 10 mM NaOH
(SD6 and 4C4/3E5 surfaces, respectively) was applied
to regenerate the surfaces at the end of each cycle and
washing steps were added to avoid carry-over. The
scrambled pentadecapeptide A15scr, injected under the
same conditions, was used as a control for non-specific
binding and instrumental drift effects.
Biosensor data were prepared, modeled and fitted by
means of BIAevaluation 3.0.2 software [17], where cal-
culations are carried out by numerical integration [18]
and global curve fitting is done by non-linear least-
squares analysis [19] applied simultaneously to the en-
tire data set. The quality of the fitted data was
evaluated by visual comparison between calculated and
experimental curves, by the magnitudes of the 2
parameter and of the standard errors associated to the
constants obtained.
2.3.2. Direct single-step kinetic analysis on peptide
surfaces
SPR experiments were also run in reverse order,
immobilized peptide and mAb as the soluble reactant.
The immobilization procedure was identical to the one
described above for mAbs, injection of 25 l of peptide
solutions (ca. 200 g ml−1 in 10 mM acetate buffer, pH
5.0) over the activated surfaces produced final immobi-
lization responses (Rimmob) of ca. 170 RU. mAb solu-
tions (in HBS buffer) ranged from 25 to 800 nM (SD6)
and from 16 to 500 nM (4C4 and 3E5) and sensorgrams
were run, modeled and fitted as above.
2.3.3. Solution-affinity SPR analysis
Peptide–Fab interactions were studied by overnight
incubation of varying peptide concentrations with a
constant total Fab concentration, followed by SPR
quantitation of the remaining free Fab at equilibrium.
Fab–peptide mixtures in HBS were incubated
overnight at 4°C, followed by 1 h re-equilibration at
25°C.
A sensor chip surface containing the wild-type pep-
tide A15S8c1 was prepared according to the manufac-
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turer’s instructions, a 5 l min−1 HBS continuous
flow was maintained and the carboxymethyl surface
was activated by a 7-min injection of a solution con-
taining 0.2 M EDC and 0.05 M NHS; A15S8c1 sur-
faces were obtained by injecting 35 l of a 200 g
ml−1 peptide solution in 10 mM sodium acetate
buffer, pH 5.5. Unreacted activated groups were
blocked by a 6-min injection of ethanolamine and
remaining non-covalently bound molecules were
washed off with a 3-min pulse of 50 mM HCl. The
final immobilization response was ca. 260 RU, corre-
sponding to a surface peptide density of ca. 0.26 ng
mm−2 (0.26 pmol). Different solutions of Fab in
HBS with known concentrations were injected over
the A15S8c1 sensor chip surface in order to calculate
a calibration curve. The peptide–Fab mixtures were
then injected over the same surface and the amount
of remaining free Fab after equilibrium was mea-
sured. All injections were run at a 5 l min−1 HBS
flow and a 2-min pulse of 50 mM HCl was used to
regenerate the surface at the end of each cycle.
Biosensor data were fitted by means of BIAevaluation
3.0.2 software. The calibration curve binding rate er-
sus Fab concentration was fitted to a four-parameter
equation and then used to calculate the free Fab con-
centrations in the equilibrium mixtures analyzed. Free
Fab dependence on peptide concentration was plotted
and the affinity binding constant (Ki) was calculated
using the Cheng and Prusoff’s formula [20] (Eq. (1)):
Ki=
(1+KA[Fab])
IC50
(1)
where IC50 is the concentration of peptide competitor
giving a 50% decrease in Fab concentration and KA is
the immobilized peptide — Fab affinity as measured
in direct kinetic SPR analysis. This formula takes into
account the influence of immobilized antigen compet-
ing with soluble antigens for the same Fab molecules.
2.4. Two-dimensional proton magnetic resonance
Spectra were acquired at 25°C, both in aqueous
solution (85% H2O+15% D2O) and in the presence
of the structuring agent TFE (30% TFE+60%
H2O+10% D2O) at a peptide concentration of 2
mM, with 1,4-dioxane added as an internal reference.
All experiments were carried out on a Varian VXR-
500 S NMR spectrometer and further processed with
the VNMR software programs. The 2D 1H-NMR [21]
experiments performed were (i) TOCSY [22] (70 ms
mixing time); (ii) NOESY [23] (200 or 400 ms mixing
time); (iii) ROESY [24] (200 ms mixing time). Water
signal elimination was carried out either upon pre-sat-
uration or using the WATERGATE [25] method.
Table 2
Specificity of the anti-GH loop mAbs assayeda
mAb 136YTASARGDLAHLTT150T
SD6
4C4
3E5
a The minimal location of SD6, 4C4 and 3E5 epitopes, as deduced
by studies with synthetic peptides and variant viruses, is outlined by
a thick line; a thinner line indicates some effect on binding of the
corresponding residues. See [4] for further details.
Prior to the Fourier transform, both FIDs and inter-
ferograms were multiplied by an exponential function.
3. Results and discussion
3.1. Direct SPR analysis of small peptides
Synthetic peptides (Table 1) reproducing the GH
loop of three type C FMDV variants were tested
against three anti-FMDV mAbs characteristic of this
antigenic site, with the specificities outlined in Table
2. In order to achieve a simple and efficient screening
of the FMDV peptides, the mAbs were immobilized
and the peptides were used as soluble analytes. As we
have shown earlier, despite the fairly small size (ca.
1.6 kDa) of the peptides, reliable data can be ob-
tained with this analysis configuration [10,11]. All the
measurable interactions fitted to the pseudo-first-order
Table 3
Affinity data for the interactions between mAbs SD6, 4C4 and 3E5,
and peptides from the G–H loops of FMDV C-S8c1, C1-Brescia and
C-S30
mAb Peptide KA(kin1) KiKA(kin2)
(M−1)a(M−1)a (M−1)a
A15SD6 5.4×107 5.0×107 6.3×107
6.5×107–1.2×107A15Bresciab
4.3×105 1.6×105 nmcA15S30
4.0×106 4.8×106 7.5×106cyc16S30
2.0×1071.1×1081.9×1084C4 A15
1.6×108A15Bresciab – 1.5×108
1.1×1072.3×1062.0×106A15S30
1.1×1081.4×108 1.8×108cyc16S30
A153E5 9.4×107 1.7×108 2.0×108
A15Bresciab 1.0×108 – 1.1×108
A15S30 8.2×1063.2×1064.5×106
8.4×1075.0×1078.4×107cyc16S30
a KA(kin1), affinity from SPR kinetic analysis with immobilized
mAb; KA(kin2), affinity from SPR kinetic analysis with immobilized
peptide; Ki(sol. aff.), affinity from solution affinity SPR analysis, using
the Cheng and Prusoff’s formula.
b Extremely small kd were observed using mAb as analyte.
c nm, non-measurable under the conditions employed.
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Fig. 1. Sensorgrams for the interactions between immobilized mAb 4C4 and peptides: (A) A15S8c1, (B) A15Brescia, (C) A15S30, (D) cyc16S30.
1:1 kinetic model and results were self-consistent [26].
Data (Table 3) showed that peptide A15S30 was only
modestly recognized relative to peptides A15S8c1 and
A15Brescia, with major differences observed in the
dissociation rate constants (Fig. 1). However, the cyclic
disulfide version of A15S30, peptide cyc16S30, dis-
played affinities comparable to those of the C-S8c1 and
C1-Brescia antigens (Table 3).
3.2. Direct SPR analysis with mAbs as analytes
Choosing peptide immobilization and mAb as ana-
lyte has some disadvantages, (1) comparison between
different peptides is often unreliable, since it is difficult
to reproduce immobilization conditions; (2) too much
peptide is required to obtain measurable immobiliza-
tion responses, leading to problems such as ligand site
heterogeneity or diffusion-controlled kinetics. Finally,
(3) the large size of the mAb tends to favor steric
hindrance and diffusion-controlled kinetics [27].
These problems were confirmed by the observation of
smaller rate constants (though giving similar affinities),
when mAb was used as analyte. This analysis configu-
ration was used only for comparison purposes, and was
not subjected to extensive optimization. A fine-tuning
of peptide immobilization would be required and, fur-
ther, Fab fragment instead of whole mAb should be
used as analyte to ensure a 1:1 binding interaction.
Anyway, results obtained in these SPR analyses were
totally consistent with the SPR data obtained in the
reverse configuration, confirming the affinity ranking
already found for the peptides under study (Table 3).
Again, major differences were observed in dissociation
rate constants (Fig. 2).
3.3. Solution affinity SPR analyses
The peptide–Fab affinity in solution was also mea-
sured by means of the SPR biosensor. The goal of this
experiment was two-fold, first, to confirm data derived
from the SPR kinetic analyses and, second, to analyze
if prolonged incubation of peptide A15S30 with the
antibody would promote peptide rearrangement to a
more antigenic conformation. Indeed, we confirmed
that most solution affinity constants were identical to
those derived from the kinetic SPR experiments. This
excellent agreement had only one remarkable exception,
peptide A15S30, for which significantly higher affinities
towards mAbs 4C4 and 3E5 were observed in solution
(Table 3, Fig. 3). This behavior of peptide A15S30 and
the higher reactivity observed for peptide cyc16S30
(Table 3, Fig. 3) highlight the pertinence of introducing
conformational constraints for accurate modeling of
the C-S30 GH loop by synthetic peptides.
3.4. Nuclear magnetic resonance studies
In view of the results obtained in the SPR analysis of
the FMDV peptides, we searched for structural ele-
ments that could account for the antigenicity rankings
observed. For this purpose, we performed a 2D-1H
NMR study of peptides A15S30 and cyc16S30 both in
water and in 30% TFE.
The first structural information withdrawn from the
NMR experiments was based on the conformational
chemical shifts. As can be seen in Fig. 4, neither peptide
shows any marked tendency to adopt a predominant
conformation in solution. The small absolute values of
the conformational chemical shifts suggest that both
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Fig. 2. Sensorgrams for the interactions between mAb 4C4 in solution and immobilized peptides: (A) A15S8c1, (B) A15Brescia, (C) A15S30, (D)
cyc16S30.
peptides exist mainly in aperiodic (random coil) form in
solution. This lack of structuration could not be
modified by environmental changes, as shown by the
similarity between conformational chemical shifts ob-
served in water and in 30% TFE. Even so, a certain
tendency to structuration in the central region of these
peptides can be distinguished. As reported earlier for
the linear (A15S8c1) and cyclic disulfide (AhxA16SS)
versions of FMDV C-S8c1 [14,28], the conformational
chemical shifts in the region that includes the RGD
tripeptide are compatible with an open turn conforma-
tion. Further, the cluster of negative conformational
chemical shifts from 143Asp to 146His could be sugges-
tive of an incipient short helix in this region, as also
reported for the C-S8c1 peptides [14,28]. A difference
between the peptides of both strains is, however, the
fact that this short helix extends, in the C-S8c1 pep-
tides, to the 147Leu residue. In the case of the C-S30
peptides, the replacement of leucine by valine at this
position seems to shorten this pre-helical stretch, and
this could be related to the lower antigenicities observed
in peptides bearing this replacement. This seems further
supported by the fact that absolute values of conforma-
tional chemical shifts are higher for cyclic peptide
cyc16S30, which is the best of the two C-S30 antigens
under study.
NOESY spectra were not particularly conclusive. A
continuous series of Ni,i+1 and Ni,i+1 nuclear Over-
hauser effects (NOEs) was observed for both peptides
either in water or in 30% TFE (not shown). These
NOEs are compatible with practically all conforma-
tions, and therefore, not very informative. Some weak
NNi,i+1 NOEs — compatible with  helix — were
observed for peptide A15S30 in 30% TFE, in the same
region where the helical stretch had been proposed (not
shown). In turn, peptide cyc16S30 displayed weak
NNi,i+1 NOEs both in water and 30% TFE (not
shown). Peak assignment was often ambiguous due to
identical chemical shifts for different HN and peak
overlap possibly prevented the detection of other infor-
mative HN–HN connectivities.
Fig. 3. Inhibition curves for peptides A15S8c1, A15Brescia, A15S30,
cyc16S30 and A15Scr (negative control) in solution affinity SPR
experiments. Note: varying concentrations of peptides were incubated
with a constant concentration of Fab overnight and remaining free
Fab was then quantitated by SPR using an A15S8c1 surface; [free
Fab]eq was plotted against peptide concentration to determine the
corresponding IC50s and thus calculate affinities (KD) by means of the
Cheng and Prusoff’s formula (see text).
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Fig. 4. Conformational chemical shift plot for peptides A15S30 (X1,
Tyr; X2, Thr; X3, – ) and cyc16S30 (X1, Cys; X2, Ahx; X3, Cys) in
water and 30% TFE.
peptide conformation appeared to play a crucial role,
since none of the replacements is directly involved in
epitope–paratope contacts. Indeed, allowing the pep-
tide to adopt a proper folding by prolonged incubation
with antibody (solution affinity SPR) or, alternatively,
inducing it into a native-like conformation by cycliza-
tion (peptide cyc16S30) led to good antigenic responses
and to a higher degree of structural similarity with
reference strain C-S8c1 peptides.
These findings have obvious implications for the
design of synthetic peptide-based vaccines, since they
reinforce the importance of peptide conformation even
when continuous (i.e. linear) epitopes are to be
mimicked.
Real-time biospecific interaction analysis, by means
of SPR biosensors, is again shown to be rather useful in
the functional analysis of antigenic determinants, allow-
ing to detect differences in peptide antigenicity that
could not be distinguished by other means, not even by
structural studies of the peptide–antibody complex.
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